Form 4: Elevation Oncology Director Alan B. Sandler Acquires 55,000 Stock Options
SEC Form 4 Filing
Director Alan B. Sandler acquired 55,000 stock options in Elevation Oncology, Inc. on February 29, 2024, according to a Form 4 filing.
Summary
- On February 29, 2024, Alan B. Sandler, a director of Elevation Oncology, Inc., acquired 55,000 stock options at an exercise price of $4.41.
- These options vest monthly over three years, starting March 29, 2024, contingent upon continued service to the company.
- Following this transaction, Sandler directly owns 55,000 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition by a director. It could be seen as slightly positive, indicating confidence, but it's not a major event.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This provides transparency to the market.
Stakeholder Impact
- Shareholders may view this as a positive sign of director confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 02/29/2024 | Date of transaction: Alan B. Sandler acquired 55,000 stock options. |
| 03/04/2024 | Date of filing: Form 4 filing date. |
| 03/29/2024 | Vesting start date: Stock options vest monthly beginning on this date. |
| 02/28/2034 | Expiration date: Stock options expire on this date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.